Comparing ChronoScale Corporation Common Stock (NASDAQ:CHRN) & Axe Compute (NASDAQ:AGPU)

Axe Compute (NASDAQ:AGPU) and ChronoScale Corporation Common Stock (NASDAQ:CHRN) are both small-cap technology companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Volatility & Risk

Axe Compute has a beta of 3.44, suggesting that its stock price is 244% more volatile than the S&P 500. Comparatively, ChronoScale Corporation Common Stock has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.

Earnings & Valuation

This table compares Axe Compute and ChronoScale Corporation Common Stock”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axe Compute	$120,000.00	791.85	-$233.10 million	($8.18)	-1.01
ChronoScale Corporation Common Stock	$12.80 million	5.82	-$11.69 million	($5.38)	-3.89

ChronoScale Corporation Common Stock has higher revenue and earnings than Axe Compute. ChronoScale Corporation Common Stock is trading at a lower price-to-earnings ratio than Axe Compute, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

9.0% of Axe Compute shares are owned by institutional investors. Comparatively, 6.4% of ChronoScale Corporation Common Stock shares are owned by institutional investors. 1.2% of Axe Compute shares are owned by company insiders. Comparatively, 6.9% of ChronoScale Corporation Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Axe Compute and ChronoScale Corporation Common Stock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Axe Compute	-470,383.31%	-7,363.67%	-626.32%
ChronoScale Corporation Common Stock	-135.66%	-197.81%	-74.17%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Axe Compute and ChronoScale Corporation Common Stock, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axe Compute	1	0	0	0	1.00
ChronoScale Corporation Common Stock	1	1	0	0	1.50

ChronoScale Corporation Common Stock has a consensus target price of $6.00, indicating a potential downside of 71.33%. Given ChronoScale Corporation Common Stock’s stronger consensus rating and higher probable upside, analysts plainly believe ChronoScale Corporation Common Stock is more favorable than Axe Compute.

Summary

ChronoScale Corporation Common Stock beats Axe Compute on 9 of the 13 factors compared between the two stocks.

About Axe Compute

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. The company provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; Ekso Indego Therapy, an adjustable and lower-limb powered exoskeleton; Ekso Indego Personal, a powered lower limb orthosis; Ekso Nomad, a power knee ankle foot orthosis; and Ekso EV, a wearable upper body exoskeleton that elevates and supports a worker's arms to assist with tasks from chest height to overhead. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in San Rafael, California.